Delving into the Latest Updates on Icodextrin with Synapse

The study aims to provide the pharmacokinetics profiles of single- and double-dose icodextrin in patients on peritoneal dialysis (PD). It may expand the available knowledge of the clinical pharmacology of icodextrin following its intraperitoneal administration and fills the gaps in our understanding of the fate of icodextrin and the metabolic consequences of icodextrin and its metabolites.

Start Date15 Aug 2024

Sponsor / Collaborator

Peking University First Hospital

NCT06492031 / RecruitingNot Applicable

Effectiveness and Safety of Icodextrin Peritoneal Dialysis Solution (Extraneal®) for Long Dwell Exchange in Peritoneal Dialysis in Patients With Chronic Renal Failure: a Multicenter, Ambispective Cohort, Observational, Real-world Study

The purpose of this study is to evaluate the effectiveness and safety of icodextrin and glucose peritoneal dialysis (PD) solutions for the long dwell exchange in PD patients with continuous ambulatory peritoneal dialysis (CAPD), and to describe medical resource utilization in patients with PD on icodextrin.

Start Date28 Jun 2024

Sponsor / Collaborator

Baxter Healthcare Ltd

NCT05943470 / Not yet recruitingPhase 4IIT

The Difference Between Daily and Alternative Day Use of Icodextrin in Peritoneal Dialysis

Volume overload is an important cause of technical failure in peritoneal dialysis patients. Icodextrin can provide continuous ultrafiltration, which provides a new option for peritoneal dialysis patients.
However, icodextrin metabolites are known to accumulate to some extent in the body, resulting in less ultrafiltration with long-term icodextrin use comparing with newly use.
Therefore, the investigator hypothesized that a single dose of icodextrin would produce more ultrafiltration volume with the use of icodextrin dialysate on alternate days than with the use of icodextrin dialysate on daily uses.

Start Date01 Aug 2023

Sponsor / Collaborator

Shanghai Renji Hospital

100 Clinical Results associated with Icodextrin

Login to view more data

100 Translational Medicine associated with Icodextrin

Login to view more data

100 Patents (Medical) associated with Icodextrin

Login to view more data

579

Literatures (Medical) associated with Icodextrin

01 Dec 2024·Behaviour Research and Therapy

Augmented Depression Therapy for young adults: A mixed methods randomised multiple baseline case series evaluation

Article

Author: Carson, James ; Loades, Maria ; Wright, Kim ; Dunn, Barnaby D ; Dunn, Barnaby D. ; Demetriou, Kalliopi ; Barlow, Gemma

Augmented Depression Therapy (ADepT) is an individual psychotherapy for depression, which has been shown to be effective in the general adult population. A randomised multiple baseline case series evaluated the feasibility, acceptability, and effectiveness of ADepT in young adults (aged 20-24). Eleven depressed young adults were recruited from a UK university wellbeing service to receive ADepT during the COVID-19 pandemic, with outcomes evaluated relative to pre-specified continuation targets. All participants received a minimum adequate treatment dose (>60% target); 89% judged ADepT as acceptable and satisfactory and would recommend it to others (>60% target); only 9% showed reliable deterioration for depression or wellbeing (meeting <30% target); and there were no trial- or treatment-related serious adverse events. Qualitative interviews revealed most participants were satisfied with and experienced benefits from ADepT. At post-treatment, reliable improvement was shown by 33% of participants for depression and 67% of participants for wellbeing (not meeting target of both >60%), with medium effect size improvements for depression (g = 0.78) and large effect size improvement for wellbeing (g = 0.93; not meeting target of both >0.80). ADepT is feasible, acceptable, and safe in young adults but may require modification to maximise effectiveness. Further research outside of the COVID-19 pandemic is warranted.

11 Oct 2024·Cureus

Long-Term Efficacy and Safety of Adhesion Prevention Agents in Abdominal and Pelvic Surgeries: A Systematic Review

Review

Author: Oliveira Souza Lima, Sergio Rodrigo ; Patel, Vaishvik K ; Kanemitsu, Kimberly ; Rashid, Muhammad ; Ali, Muhammad

This systematic review evaluates the long-term efficacy and safety of adhesion prevention agents in abdominal and pelvic surgeries, synthesizing data from randomized controlled trials and meta-analyses. Adhesions, common postoperative complications, can lead to significant morbidity, including chronic pain, infertility, and bowel obstruction. Various agents, including hyaluronic acid-carboxymethylcellulose films and icodextrin solutions, have been developed to mitigate these risks. Our review highlights that agents like bioresorbable membranes (Seprafilm) and icodextrin significantly reduce the incidence and severity of adhesions, particularly in high-risk surgeries. However, certain complications such as anastomotic leaks and infections are associated with some agents, emphasizing the need for careful consideration in clinical decision-making. Additionally, while these agents reduce postoperative morbidity and enhance recovery, further research is needed to assess their long-term impact, particularly regarding fertility outcomes and chronic pain. This review underscores the importance of integrating adhesion prevention agents into surgical protocols, which has the potential to reduce healthcare costs, improve patient outcomes, and optimize postoperative care pathways. Standardization of adhesion prevention practices could further enhance surgical efficiency and patient recovery, particularly in high-risk patient populations and complex surgeries.

01 Sep 2024·Artificial Organs

Oxidative stress reduction by icodextrin‐based glucose‐free solutions in peritoneal dialysis: Support for new promising approaches

Article

Author: Bertoldi, Giovanni ; Bettin, Elisabetta ; Calò, Lorenzo A ; Baldini, Paola ; Basso, Anna ; Cacciapuoti, Martina ; Caputo, Ilaria ; Driussi, Giulia

AbstractBackgroundOxidative stress (OxSt) and inflammation are common in CKD and are known CV and mortality risk factors. In peritoneal dialysis (PD) OxSt and Inflammation even increase due to the use of glucose‐based solutions.Patients and MethodsThis study analyzed in 15 PD patients the effect of 3 and 6 months of treatment with icodextrin‐based glucose‐free solutions on OxSt and inflammation, evaluating p22phox protein expression (Western blot), NADPH oxidase subunit, essential for OxSt activation, MYPT‐1 phosphorylation state, marker of RhoA/Rho kinase pathway (ROCK) activity, involved in the induction of OxSt (Western blot) and Malondialdehyde (MDA) production (fluorimetric assay). Interleukin (IL)‐6 blood level (chemiluminescence assay) has been measured and used as a marker of inflammation.Resultsp22phox protein expression, MYPT 1 phosphorylation, and MDA were reduced after 3 months from the start of icodextrin (1.28 ± 0.18 d.u. vs. 1.50 ± 0.19, p = 0.049; 0.89 ± 0.03 vs. 0.98 ± 0.03, p = 0.004; 4.20 ± 0.18 nmol/mL vs. 4.84 ± 0.32 nmol/mL, p = 0.045, respectively). In a subgroup of 9 patients who continued the treatment up to 6 months, MYPT‐1 phosphorylation was further reduced at 6 months compared to baseline (0.84 ± 0.06 vs. 0.99 ± 0.04, p = 0.043), while p22phox protein expression was reduced only at 6 months versus baseline (1.03 ± 0.05 vs. 1.68 ± 0.22, p = 0.021). In this subgroup, MDA was reduced at 6 months versus baseline (4.03 ± 0.24 nmol/mL vs. 4.68 ± 0,32, p = 0.024) and also versus 3 months (4.03 ± 0.24 vs. 4.35 ± 0.21, p = 0.008). IL‐6 level although reduced both at 3 and 6 months, did not reach statistical significance.ConclusionsThe reduction of OxSt with icodextrin‐based PD solutions, although obtained in a small patients cohort and in a limited time duration study, strongly supports the rationale of using osmo‐metabolic agents‐based fluids replacing glucose‐based fluids. Ongoing studies with these agents will provide information regarding preservation of peritoneal membrane integrity, residual renal function, and reduction of CVD risk factors such as OxSt and inflammation.

100 Deals associated with Icodextrin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03266	Icodextrin	V07AB	DB00702

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Kidney Diseases	JP	-	29 Nov 2003
Kidney Failure, Chronic	-	Baxter International, Inc.	01 Jan 1994

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart Failure	Preclinical	US	Baxter Healthcare Corp.	01 Aug 2006
Heart Failure	Preclinical	AU	Baxter Healthcare Corp.	01 Aug 2006
Heart Failure	Preclinical	CA	Baxter Healthcare Corp.	01 Aug 2006
Heart Failure	Preclinical	BE	Baxter Healthcare Corp.	01 Aug 2006
Hypertriglyceridemia	Discovery	KR	Takeda Pharmaceutical Co., Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASN2022	Not Applicable	-	-	Icodextrin	(vncboxmjrj) = nqvjbgzrpq jjjgqbixps (qhmbnkygix, 1.2) View more	-	04 Nov 2022
ERA2020	Not Applicable	-	8	Icodextrin	dcbmcvzjtp(xjkbtqvjch) = hprnntxvfo upfkxvkhfc (qbwjmiuezj, 27) View more	Positive	06 Jun 2020
				Icodextrin	dcbmcvzjtp(xjkbtqvjch) = hiwwnppcbr upfkxvkhfc (qbwjmiuezj, 34) View more
SP503 (ERA2019)	Not Applicable	-	531	Icodextrin	(fdwknaezbv): HR = 0.499 (95% CI, 0.331 - 0.752), P-Value = 0.001	Positive	13 Jun 2019
				Icodextrin
ERA2019	Not Applicable	Pleural Effusion	-	ICODEXTRIN	cxrqjckadc(oxuwuopdqq) = yszrqrpjld cafupgrezs (otzyqojfnl )	-	13 Jun 2019
				ICODEXTRIN	cxrqjckadc(oxuwuopdqq) = sxusudjsqd cafupgrezs (otzyqojfnl )
ASN2018	Not Applicable	Hyponatremia	98	Icodextrin	(zisasgqaoh): OR = 1.88, P-Value = 0.01	Positive	23 Oct 2018
				Icodextrin
ISRCTN14931270 (Pubmed \| BMC Nephrol)	Not Applicable	-	43	Icodextrin solution	bfqftedllo(qktfmkuzmt) = mahbgzzqid bfoepexdpj (verufholtr )	-	08 May 2018
				Glucose-based solution	syiavwaxab(lurgagmudv) = vobksgqozm atfzlffimc (zgrmtvrgrj ) View more
ASN2017	Not Applicable	-	15	Icodextrin	xxqcqdaqpv(weyvhyigfl): P-Value = 0.448 View more	Positive	31 Oct 2017
				Uni-PET with preceding 7.5% icodextrin long nocturnal dwell
NCT02318888 (ADEPT, Pubmed \| Colorectal Dis)	Not Applicable	Small intestine obstruction	300	icodextrin (Standard surgery)	cbfadveexx(khkovqsxuy) = pbzyszeupa ustyvpvnvm (csupdgibrq )	-	01 Mar 2016
				Standard surgery with icodextrin instillation	cbfadveexx(khkovqsxuy) = tyxsnexwul ustyvpvnvm (csupdgibrq )
Taiwan National Health Insurance Research Database (ASN2014)	Not Applicable	high transporters \| high-glucose containing dialysates	1,627	Icodextrin	nomfphcvbm(acofsjxqco): HR = 0.6 (95% CI, 0.37 - 0.99), P-Value = 0.045	Positive	11 Nov 2014
				Non-Icodextrin
ASN2014	Not Applicable	-	86	Icodextrin	atquiqnzao(losqyqzmjs) = iizomnmgqw rwhwlgqdve (olsygbknoc )	Negative	11 Nov 2014
				Dextrose based PD solutions	atquiqnzao(losqyqzmjs) = oxhwtpuilw rwhwlgqdve (olsygbknoc )